GlassScriptPhysician profile
Amy F Drossman
NPI 1639555873
$3,040.63
in general payments reported to CMS, 2019-2025
23 companies · $723 in 2025
The $723 reported for 2025 was more than what 86% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $400 · 2020: $15.00 · 2021: $492 · 2022: $387 · 2023: $472 · 2024: $552 · 2025: $723.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,747.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,746.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $482.98 | 2019-2025 | Hydrus Microstent, Tryptyr, Total30 |
| Bausch & Lomb Americas INC. | $390.91 | 2022-2025 | Xiidra, Miebo, Infuse |
| Biotissue Holdings INC. | $373.13 | 2024-2025 | |
| Ivantis, INC | $304.47 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $275.07 | 2021-2022 | |
| Allergan, INC. | $239.35 | 2019-2022 | |
| Johnson & Johnson Vision Care, INC. | $196.84 | 2022-2025 | Acuvue |
| Horizon Therapeutics Plc | $124.99 | 2023 | Tepezza |
| Apellis Pharmaceuticals, INC. | $124.48 | 2024 | Syfovre |
| Kala Pharmaceuticals, INC. | $85.86 | 2021-2022 | |
| Tarsus Pharmaceuticals, INC. | $75.40 | 2024-2025 | Xdemvy |
| Dompe US, INC. | $57.29 | 2022-2025 | Oxervate |
| Sun Pharmaceutical Industries INC. | $52.89 | 2019-2025 | |
| Abbvie INC. | $50.35 | 2022-2023 | Vuity, Alphagan P, Lumigan |
| Harrow Eye, LLC | $44.26 | 2024-2025 | Vevye |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $43.46 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $31.20 | 2020-2021 | |
| Rayner Intraocular Lenses Limited | $18.46 | 2022 | |
| Oyster Point Pharma, INC. | $15.00 | 2024 | Tyrvaya |
| Shire North American Group INC | $14.78 | 2019 | |
| Amgen INC. | $13.45 | 2024 | Tepezza |
| Aerie Pharmaceuticals, INC. | $13.33 | 2019 | |
| Glaxosmithkline, LLC. | $12.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Drossman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.